CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

Status Recruiting

Clinical Trial Summary

This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)

Clinical Trial Description

1. Choose appropriate advanced cancer patients with Claudin6, GPC3, Mesothelin, or AXL expression, with written consent for the study; 2. Perform PBMCs apheresis from the patient and isolate NK cells, transfect the NK cells with Claudin6, GPC3, Mesothelin, or AXL targeting CAR, amplify the number of transfected NK cells as needed, test the quality and killing activity of the Claudin6, GPC3, Mesothelin, or AXL-CAR-NK cells and then transplant back the patients via systemic or local infusions (via artery or intra-tumor), and follow up closely to collect related results as needed; 3. To enhance the killing capability, some CAR-NK cells are genetically engineered to express and secret IL7/CCL19 and/or SCFVs against PD1/CTLA4/Lag3; some CAR-NK cells are combined with Cannabidiol(CBD) or Nicotinamide adenine dinucleotide (NAD); 4. Evaluate the clinical results as needed. 5. Will also perform the similar clinical trial on different cancer types with Claudin6, GPC3, Mesothelin, or AXL expression. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05410717
Study type	Interventional
Source	Second Affiliated Hospital of Guangzhou Medical University
Contact	Zhenfeng Zhang, MD, PHD
Phone	+862039195966
Email	zhangzhf@gzhmu.edu.cn
Status	Recruiting
Phase	Phase 1
Start date	June 1, 2022
Completion date	May 31, 2034

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01010126` - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	Phase 2
Terminated	`NCT00899093` - YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
Completed	`NCT00301756` - Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors	Phase 2
Completed	`NCT00262847` - Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Phase 3
Recruiting	`NCT01000259` - Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer	N/A
Completed	`NCT00066456` - Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer	Phase 1
Withdrawn	`NCT00551265` - Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy	N/A
Active, not recruiting	`NCT03188432` - Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Phase 2
Completed	`NCT03297489` - Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer	Early Phase 1
Withdrawn	`NCT00053235` - Research Study in Patients With Advanced Ovarian Epithelial Cancer	N/A
Completed	`NCT00194714` - Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab	Phase 1/Phase 2
Terminated	`NCT02441140` - Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis	N/A
Completed	`NCT01131234` - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT00003532` - Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer	Phase 2
Completed	`NCT01522820` - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors	Phase 1
Completed	`NCT01551745` - Salvage Ovarian FANG™ Vaccine + Bevacizumab	Phase 2
Not yet recruiting	`NCT06315270` - To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
Recruiting	`NCT05659381` - Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer	Phase 3
Withdrawn	`NCT02872519` - PET Imaging of Ovarian Carcinoma With 18F-FSPG	Early Phase 1
Withdrawn	`NCT02567396` - Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction	Phase 1